Piramal Pharma Ltd. Continues to Invest In USA; $90M in Expansions of Two US Sites
Addition of commercial-scale sterile injectables capabilities in Lexington, KY
Addition of development and commercial-scale capabilities in payload-linkers for bioconjugates in Riverview, MI
This is incremental to Piramal's prior investments of $570 M in the US
MUMBAI, India, May 12, 2025 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, in conjunction with the 2025 SelectUSA Investment Summit, commits to a $90M investment plan towards expanding two of the Company's US facilities. These expansions are in response to ongoing demand from US customers, in support of the trend towards US onshoring of drug supply, and in line with Piramal Pharma's overall belief in the value and benefits of US-based innovation. In both cases, Piramal Pharma is making brownfield expansions to existing sites, financed by bank loans and internal accruals, which is the fastest, lowest risk, and most economical way to add new capacities to the US market.
Piramal Pharma's Lexington, Kentucky, facility specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The site's expansion—which includes 24,000 square feet of manufacturing space and a new laboratory—adds commercial-scale manufacturing that will enable the efficient scale-up of clients' injectable drug products. Key additions include a new filling line, two commercial-size lyophilizers, a special capping machine, and an external vial washer. The facility is expected to be completed and online by late 2027.
Piramal Pharma's Riverview, Michigan site, has earned a reputation as an industry leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs) over the past 50+ years. Here, the company is adding a commercial-scale suite specifically for the development and manufacturing of payload-linkers. These high potency APIs are used in the development of antibody-drug conjugates (ADCs) and other bioconjugate drugs. The new payload-linker suite is expected to be operational before the end of 2025.
These site expansions are expected to generate greater opportunities for integrated ADC projects. Working synergistically, they will play a vital role in Piramal Pharma's integrated ADC development and manufacturing program, branded ADCelerate™. With development and commercial-scale capabilities in mABs, payload-linkers, conjugations, and fill/finish, ADCelerate speeds timelines, enabling project initiation to GMP drug product in just 12 months with uncompromised quality. This capability strengthens Piramal Pharma's position as an efficient and reliable global partner for biologic manufacturing.
"Since its inception, Piramal Pharma Ltd has invested $570 million in its US drug development and manufacturing capabilities," said Peter DeYoung, Chief Executive Officer, Global Pharma. "The US is our largest market, where we currently employ approximately 750 people. Expanding the capacities and offerings in these two plants in the US, along with the prior major investments made in our Sellersville PA drug product facility, and our inhalation anesthesia drug substance and drug product facility in Bethlehem PA, will support our customers who value our offerings in an onshore setting."
As a patient centric organization, Piramal Pharma is committed to supporting our customers in their quest to reduce the burden of disease on patients. These expansions bring commercial-scale support to two important and fast-growing segments of drug development. Payload-linkers are fundamental to the process of building bioconjugates, which are the platform for numerous oncology drugs. Sterile fill/finish represents the final stage of manufacturing for injectable drugs. Collectively, these expansions support our integrated drug development and manufacturing services and will ultimately get more treatments into patients on faster timelines.
About Piramal Pharma Limited:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.
For more information, visit: Piramal Pharma | LinkedIn
* Includes one facility via PPL's minority investment in Yapan Bio.
Photo: https://mma.prnewswire.com/media/2685022/Peter_DeYoung_CEO_Piramal.jpgPhoto: https://mma.prnewswire.com/media/2685019/New_Lexington_facility.jpgPhoto: https://mma.prnewswire.com/media/2685018/Riverview_site_expansion.jpgLogo: https://mma.prnewswire.com/media/1855206/4913155/Piramal_Pharma_Limited_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/piramal-pharma-ltd-continues-to-invest-in-usa-90m-in-expansions-of-two-us-sites-302452443.html
SOURCE Piramal Pharma Ltd
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/12/c8978.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Loving Giving Local: Rhoxon Productions
Movie enthusiasts will benefit from this week's Loving Giving Local donation. A local movie production company that sponsors a film festival is this week's recipient. Rhoxon Productions got a financial gift from Auto Express Resale Center. Rhoxon is an Erie-based non-profit independent film company that creates organic stories that promote a positive change. Besides creating art, Rhoxon strives to create jobs and educational opportunities in the film industry. 'Our last few projects have been about healing and about coping, and our next two are about revamping the social justice system,' said Katie Nixon, RhoxonProductions co-founder. 'That's sort of our creative endeavors, and we also create educational opportunities for people to learn how to do this professionally.' Nixon says Rhoxon has a vision of creating 50 new jobs in the film industry here. And she insists you no longer have to be on the East or West Coast to have a film career. 'No, the landscape has changed so much. Even Netflix has created their new studio out in Jersey. It's not just that you have be in New York or LA,' she explained. 'Erie is kinda a really interesting place. You have beach, you have woods, you have city, you have country all within 15 minutes of each other.' That landscape diversity, Nixon said, makes Northwest Pennsylvania the perfect place for shooting movies. This week's Loving Giving Local donation will help support an upcoming film festival. Nixon said, 'We started the only multi-genre film festival here in Erie. It's the Lake Effect Film Festival, which will be in September. So that money will go to help make that event possible.' After making his check presentation, Joe Askins of Auto Express Resale Center said, 'We're pretty fortunate to have Rhoxon in our community and they're already doing great things. So for us to be able to deliver loving giving local and to learn the donation we bring is going toward their film festival, that's what Loving Giving Local is all about,' Askins said. You can learn more about the film festival and Rhoxon's work here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
25 minutes ago
- Yahoo
Rockford hydroelectric project aims to power five homes with clean energy
ROCKFORD, Ill. (WTVO) — A Rockford-based company wants to harness the Rock River to produce energy to power homes. Latitude Power of Rockford partnered with design firm Studio GWA to create a pilot project that would use hydroelectric generators to create enough clean energy to supply electricity to five homes. 'Essentially, it takes wasted energy that's either flowing over a dam, or anywhere water is falling,' said Jared Cacciatore, Latitude Power co-founder. Rockford's Fordam dam will soon become the pilot program's test site, where a micro hydroelectric generator will be installed. 'We can take that water, that which is potential energy, and turn it into mechanical energy through a turbine and a generator, and then turn that into, you know, electrical energy,' Cacciatore said. Latitude Power received state funding through Illinois' Climate and Equitable Jobs Act (CEJA) to help develop the project. 'The company here won a nearly $1 million grant to produce hydroelectric power and uses the Rock River to generate electricity, which is a great concept. The Rock River has been a huge asset for this area, so it seems to be the next step in using this asset to generate clean power and provide electricity throughout the area,' said Sen. Steve Stadelman (D-Rockford). Latitude has already done smaller-scale testing, but moving to the Rock River means new challenges. 'It performs pretty, pretty well at the wastewater plant. But this is a new environment. It's a new, you know, there are new challenges. Will it will it be safe from vandalism? Will we be safe from other things we haven't thought of?' Cacciatore said. The company hopes the pilot project will generate enough electricity to power five homes. If successful, it plans to scale up from there. 'We want to help to help Rockford become a beacon of clean energy, a beacon of collaborative community involvement and advocacy for each other and for for the community and for the the greater good for the planet,' Cacciatore said. Once the grant funding is in place, Latitude hopes to have the project done within 18-20 months. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
27 minutes ago
- Yahoo
US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter patent for the medication Nuplazid, which treats psychosis in Parkinson's disease. A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments. The verdict supports ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in its legal struggle with India-based MSN Laboratories and upholds a December 2023 ruling by the U.S. District Court of Delaware. A later patent claim with the same priority date cannot be declared invalid by the court. According to CEO Catherine Owen Adams, Nuplazid's patent protection has been extended to 2030. The 34 mg capsule is also protected by a separate formulation patent that runs through 2038. The U.S. FDA authorized Nuplazid in 2016 to treat delusions and hallucinations linked to psychosis in Parkinson's disease. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)'s legal stance in a different action against Aurobindo Pharma was further strengthened by the latest decision. When taken as a whole, these results solidify the company's portfolio of intellectual property in the face of generic competition, guaranteeing prolonged market exclusivity for its flagship neurological medication. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical firm that specializes in the creation and marketing of medications that treat uncommon diseases and disorders of the central nervous system. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
